Wilfried Seifert

Director Clinical Development
CSL Behring, Marburg, Germany

Presentation(s):

• OC 63.3 - Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B

  Tuesday, July 12, 2022
  3:15 PM – 3:30 PM